IPOs and Secondaries
IPOs and Secondaries Articles
Rev Group has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Myovant Sciences registered an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price 13 million shares in...
Published:
Last Updated:
Three of last week's four initial public offering candidates succeeded in reaching the public markets, but only one had what we could call a positive experience.
Published:
Last Updated:
Intrepid Aviation has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Now some investors are going to have to consider if this 7 million share underwritten secondary offering at $40 per share came at a fair price.
Published:
Last Updated:
iRhthym Technologies has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
Published:
Last Updated:
Smart Sand has amended its filing with the U.S. Securities and Exchange Commission regarding its initial public offering.
Published:
Last Updated:
Valvoline has seen its quiet period come to an end after the company's successful initial public offering from September.
Published:
Last Updated:
BlackLine expects to price more than 8 million shares in the range of $13 to $15 per share for an initial public offering valued up to more than $148 million.
Published:
Last Updated:
Quantenna Communications intends to price more than 6 million shares in the range of $14 to $16 per share in an initial public offering valued up to more than $123 million.
Published:
Last Updated:
Tuesday brought the expiration of two IPO quiet periods, so analysts at the underwriting firms can now issue coverage ratings and price targets on the companies.
Published:
Last Updated:
Myovant Sciences expects to price its 13 million shares in the range of $12 to $15 per share for an initial public offering valued up to more than $224 million.
Published:
Last Updated:
There may be other calls in the coming days, but so far we have seen mostly positive analyst coverage now that the Trade Desk quiet period has ended.
Published:
Last Updated:
Acushnet expects to price more than 19 million shares in the range of $21 to $24 per share for an initial public offering valued up to more than $533 million.
Published:
Last Updated: